Continually Updated Clinical Reference
 
 
  All Sources     eMedicine     Medscape     Drug Reference     MEDLINE
 
eMedicine - Sjogren Syndrome : Article by

Quick Find
Authors & Editors
Introduction
Clinical
Differentials
Workup
Treatment
Medication
Follow-up
Miscellaneous
References

Related Articles
Anxiety

Arthritis, Rheumatoid

Candidiasis

Conjunctivitis

Corneal Abrasion

Corneal Ulceration and Ulcerative Keratitis

Gingivitis

HIV Infection and AIDS

Multiple Sclerosis

Mumps

Myopathies

Systemic Lupus Erythematosus




Patient Education
Arthritis Center

Sjögren Syndrome Overview

Sjögren Syndrome Causes

Sjögren Syndrome Symptoms

Sjögren Syndrome Treatment




Author: Darren Phelan, MD, Medical Director, Department of Emergency Medicine, Sierra Nevada Memorial Hospital

Editors: Daniel J Dire, MD, FACEP, FAAP, FAAEM, Clinical Associate Professor, Department of Emergency Medicine, University of Texas-Houston; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Gino A Farina, MD, Program Director, Associate Professor of Clinical Emergency Medicine, Department of Emergency Medicine, Long Island Jewish Medical Center, Albert Einstein College of Medicine; John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center; Charles V Pollack, Jr, MD, MA, FACEP, Professor, Department of Emergency Medicine, University of Pennsylvania College of Medicine; Chairman, Department of Emergency Medicine, Pennsylvania Hospital

Author and Editor Disclosure

Synonyms and related keywords: Sjogrens syndrome, Sjogren's, Sjogrens, Sjogren's syndrome, autoimmune disease, Sjögren syndrome, Sjögren's syndrome, sicca complex, Gougerot-Sjögren disease, sicca syndrome, Sjögren disease, Sjögren's disease, xerostomia, dry mouth, xerophthalmia, dry eyes, lymphocytic infiltration of the exocrine glands, autoimmune disorder, exocrine gland dysfunction, systemic lupus erythematosus, SLE, rheumatoid arthritis, scleroderma, systemic sclerosis, cryoglobulinemia, polyarteritis nodosa, rheumatologic disorder

Background

Sjögren syndrome is a chronic autoimmune disorder characterized by xerostomia (dry mouth), xerophthalmia (dry eyes), and lymphocytic infiltration of the exocrine glands. This triad is also known as the sicca complex.

Sjögren syndrome displays a wide spectrum of severity and can go undiagnosed for several months to years. The Swedish physician Henrik Sjögren first described the syndrome in 1933.

For a CME activity, see Systemic Lupus Erythematosus and Sjögren's Syndrome: Highlights From ACR 2007. For more information, see Medscape's Sjögren's Syndrome Resource Center.

Pathophysiology

Sjögren syndrome can occur as a primary disease of exocrine gland dysfunction or in association with several other autoimmune diseases (eg, systemic lupus erythematosus [SLE], rheumatoid arthritis, scleroderma, systemic sclerosis, cryoglobulinemia, polyarteritis nodosa). These primary and secondary types occur with similar frequency, but the sicca complex seems to cause more severe symptoms in the primary form.

Virtually all organs may be involved. The disease commonly affects the eyes, mouth, parotid gland, lungs, kidneys, skin, and nervous system.

Frequency

United States

Sjögren syndrome is estimated to be the second most common rheumatologic disorder, behind only SLE.

International

Comparative studies between different ethnic groups have suggested that Sjögren syndrome is a homogeneous disease that occurs worldwide with similar prevalence and affects 1-2 million people.

Mortality/Morbidity

  • Although the disease process rarely shortens a patient's lifespan, morbidity can be devastating. Ocular dryness can lead to chronic keratoconjunctivitis and corneal ulcers. Oral dryness leads to caries, fissures, candidal infections, and difficulty speaking and swallowing food. These patients often are undiagnosed or misdiagnosed for years. They often feel clinicians are uneducated or unsympathetic to their disease.
  • As a result of the lymphocytic infiltration, 10% of patients may develop pseudolymphoma, a lymphoproliferative process. Approximately 10% of these patients can develop non-Hodgkin lymphoma (1% of all patients with Sjögren syndrome).

Sex

The female-to-male ratio of Sjögren syndrome is 9:1.

Age

Peak incidence occurs in the fourth and fifth decades of life.



History

Onset of Sjögren syndrome is insidious, and symptoms may be mild.

  • Dry eyes and/or mouth (required for the clinical diagnosis)
  • Musculoskeletal (60%)
    • Fatigue (60%)
    • Arthralgias (60-70%)
    • Myalgias (20-30%)
  • Dry skin (40%)
  • Vaginal dryness (40%)

Physical

The Sjögren syndrome may be mild or hard to detect clinically.

  • Keratoconjunctivitis
  • Salivary insufficiency
  • Vasculitis (25%)
  • Lymphadenopathy (20%)
  • Polyneuropathies (10-15%)
  • Renal involvement
    • Glomerulonephritis
    • Interstitial nephritis
  • Parotid gland enlargement (usually bilateral)



Anxiety
Arthritis, Rheumatoid
Candidiasis
Conjunctivitis
Corneal Abrasion
Corneal Ulceration and Ulcerative Keratitis
Gingivitis
HIV Infection and AIDS
Multiple Sclerosis
Mumps
Myopathies
Systemic Lupus Erythematosus

Other Problems to be Considered

Neuropathies
Medication side effects (dry mouth especially)



Lab Studies

  • Schirmer test
    • The Schirmer test is probably the only test available in the ED to strongly support or refute suspicion of Sjögren syndrome.
    • A test strip of number 41 Whatman filter paper is placed near the lower conjunctival sac to measure tear formation.
    • Healthy persons wet 15 mm or more after 5 minutes. A positive test occurs when less than 5 mm is wet after 5 minutes.
  • Erythrocyte sedimentation rate (ESR) is elevated in 80% of patients.
  • Rheumatoid factor is present in 52% of cases of primary-type Sjögren syndrome and in 98% of secondary-type cases.
  • Complete blood count (CBC)
    • A mild normochromic normocytic anemia is present in 50% of patients.
    • Leukopenia occurs in up to 42% of patients.
  • Autoantibodies (outside of ED)
    • Anti-SS-A and anti-SS-B are present in most cases of primary-type Sjögren syndrome, while antisalivary duct antibodies are present in most cases of the secondary type.
    • Antinuclear antibodies of the speckled and homogeneous type are present in most cases of primary Sjögren syndrome.
  • Creatinine clearance may be diminished in up to 50% of patients.

Imaging Studies

  • No imaging studies are helpful in the initial diagnosis of Sjögren syndrome. However, CT scan could be helpful if progression to lymphoma is suspected. This may not be necessary in the emergent setting. MRI of the salivary glands can also be performed outside the ED setting for intraglandular and extraglandular duct dilatations and duct strictures that can be seen with chronic sialadenitis.

Other Tests

  • Rose bengal staining is a test performed on an outpatient basis to confirm ocular involvement.

Procedures

  • Minor salivary gland or lower lip biopsy
    • For histopathologic confirmation of exocrine gland infiltration
    • Outside the scope of the ED



Emergency Department Care

  • Diagnosis of Sjögren syndrome can be made from the ED if the index of suspicion is high.
  • Patients may present with mild symptoms (eg, eye grittiness, eye dryness or discomfort, dry mouth, recurrent caries). Bilateral parotid gland swelling is also a common presentation.
  • Patients with known Sjögren syndrome should not be taken lightly for their complaint of dry eyes or dry mouth, as these chronic problems can be very distressing and obtrusive.

Consultations

  • Surgical consultation for lip biopsy as an outpatient is needed to histologically confirm the diagnosis.
  • All patients with known or suspected Sjögren syndrome should be referred to a rheumatologist.



Aids to lubrication are the mainstay of therapy for the ocular and oral complications of Sjögren syndrome. No cure for this disease exists.

Drug Category: Lubricants

These agents may be needed every 1-3 h. Thicker, longer-acting drops are available, but they may cause blurring of vision due to the film produced on the cornea and are more appropriate for bedtime use.

Drug NameArtificial tears (Celluvisc, Murine, Refresh)
DescriptionContain equivalent of 0.9% NaCl and are used to maintain ocular tonicity. Act to stabilize and thicken precorneal tear film and prolong tear film breakup time, which occurs with dry eye states.
Adult Dose1-2 gtt tid/qid prn
Pediatric DoseAdminister as in adults
ContraindicationsDocumented hypersensitivity
InteractionsNone reported
PregnancyA - Fetal risk not revealed in controlled studies in humans
PrecautionsHyperemia, photophobia, stickiness of eyelashes, ocular discomfort, or irritation may occur

Drug Category: Salivary aids

Use of sugarless chewing gums and salivary substitutes assists in management of oral symptoms.

Drug NamePilocarpine (Salagen)
DescriptionThis may increase salivary and lacrimal flow rates in some patients but should not be administered in the ED. Prescriber may wish to write prescription for patient to take home.
Adult Dose5 mg PO qd; improvement evident following 6 wk of treatment
Pediatric DoseNot established
ContraindicationsDocumented hypersensitivity; acute inflammatory disease of anterior chamber
InteractionsMay be ineffective when used concomitantly with nonsteroidal anti-inflammatory agents
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsCaution in acute cardiac failure, peptic ulcer, hyperthyroidism, GI spasm, bronchial asthma, Parkinson disease, recent MI, urinary tract obstruction, and hypertension or hypotension

Drug Category: Cholinergic agents

These agents increase activity of exocrine glands, including salivary glands.

Drug NameCevimeline (Evoxac)
DescriptionBinds to cholinergic (muscarinic) receptors, causing increase in secretion of salivary glands.
Adult Dose30 mg PO tid
Pediatric DoseNot established
ContraindicationsDocumented hypersensitivity; narrow-angle glaucoma; acute iritis; uncontrolled asthma
InteractionsMay have additive effects when used with other cholinergic agents; concurrent use with beta-blockers may cause potential for cardiac conduction disturbances; CYP2D6 inhibitors (eg, fluoxetine, amiodarone, quinidine, ritonavir, paroxetine) or CYP3A3/4 (eg, itraconazole, diltiazem, ketoconazole, verapamil) may increase toxicity; anticholinergic agents (eg, phenothiazines, TCAs, atropine) may decrease effects of cevimeline
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsCaution in cardiovascular disease, controlled asthma, COPD, or chronic bronchitis; may induce smooth muscle spasms and precipitate cholangitis, biliary obstruction, cholecystitis, or urethral reflux in patients with history of biliary stones or nephrolithiasis

Drug Category: Immunosuppressive agents

These agents are used with varying degrees of success for glomerulonephritis, interstitial pneumonitis, and pseudolymphoma. They do not appear to aid in the oral or ocular manifestations.

Drug NameCyclosporine (Restasis)
DescriptionUsed to relieve dry eyes caused by suppressed tear production secondary to ocular inflammation. Thought to act as partial immunomodulator. Exact mechanism of action is not known.
Adult DoseInstill 1 gtt in each eye q12h
Pediatric Dose<16 years: Not established
>16 years: Administer as in adults
ContraindicationsDocumented hypersensitivity; ocular infection
InteractionsNone reported
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsHerpes keratitis; do not administer while wearing contact lenses; may cause ocular burning, conjunctival hyperemia, ocular discharge, excessive tearing, eye pain, foreign body sensation, pruritus, stinging, or blurred vision

Drug NameHydroxychloroquine (Plaquenil)
DescriptionMay be useful in treating arthralgias and skin symptoms, but it has not been shown to affect salivary or lacrimal gland function. Patients with evidence of marked immune dysregulation may benefit from prophylactic therapy with hydroxychloroquine to prevent progression to extraglandular sites.
Hydroxychloroquine sulfate 200 mg is equivalent to 155 mg hydroxychloroquine base and 250 mg chloroquine phosphate.
Adult Dose200 mg PO qd
Pediatric DoseNot established
ContraindicationsDocumented hypersensitivity; psoriasis; retinal and visual field changes attributable to 4-aminoquinolones
InteractionsSerum levels increase with cimetidine; magnesium trisilicate may decrease absorption
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsCaution in hepatic disease, G-6-PD deficiency, psoriasis, and porphyria; not recommended for long term in children; perform periodic (6 mo) ophthalmologic examinations; test periodically for muscle weakness



Further Inpatient Care

  • Give attention to artificial lubricants and humidified oxygen to intubated and/or sedated patients with Sjögren syndrome.

Further Outpatient Care

  • Patients should be encouraged to avoid activities that increase the dryness symptoms (eg, smoking, low-humidity environments).
  • All patients with Sjögren syndrome should be monitored by an ophthalmologist and dentist, in addition to their rheumatologist.
  • Certain patients may be candidates for punctal occlusion, usually performed by an ophthalmologist.
  • The Sjögren Syndrome Foundation, Incorporated, was founded in 1983 and is a good resource for patients. Contact the foundation at 6707 Democracy Blvd, Ste 325, Bethesda, MD, 20817; (800) 475-6473, (301) 530-4415 (fax).

Complications

  • The sicca complex of Sjögren syndrome rarely leads to serious complications, but potential problems with other associated rheumatic diseases must be considered.
  • A very small risk (1%) of progression to non-Hodgkin lymphoma does exist.

Prognosis

  • Prognosis of Sjögren syndrome is good from the standpoint of mortality, but it has significant morbidity.
  • Patients can be reassured that the Sjögren syndrome itself will not shorten their lifespan.

Patient Education



Medical/Legal Pitfalls

  • Medical pitfalls include failure to recognize Sjögren syndrome. Many times, the symptoms of dry or itchy eyes may be attributed to conjunctivitis or allergic symptoms. Prompt referral from the ED may assist in making a positive diagnosis much sooner.



  • Anaya J, Talal N. Sjögren's syndrome and connective tissue diseases associated with other immunologic disorders. In: WJ Koopman, ed. Arthritis and Allied Conditions: A Textbook of Rheumatology. 13th ed. Baltimore: Williams & Wilkins; 1997:1561-80.
  • Isenberg DA. Systemic lupus erythematosus and Sjögren's syndrome: historical perspective and ongoing concerns. Arthritis Rheum. Mar 2004;50(3):681-3. [Medline].
  • Lane HC, Fauci AS. Sjögren's syndrome. In: Harrison's Principles of Internal Medicine. 11th ed. New York: McGraw-Hill; 1987:1433-34.
  • Ramos-Casals M, Brito-Zeron P, Garcia-Carrasco M, Font J. Sarcoidosis or Sjogren syndrome? Clues to defining mimicry or coexistence in 59 cases. Medicine (Baltimore). Mar 2004;83(2):85-95. [Medline].
  • Talal N. Sjögren's syndrome: historical overview and clinical spectrum of disease. Rheum Dis Clin North Am. Aug 1992;18(3):507-15. [Medline].
  • Wallach J. Interpretation of Diagnostic Tests: A Synopsis of Laboratory Medicine. 4th ed. Boston: Little, Brown; 1986:321-3.

Sjogren Syndrome excerpt

Article Last Updated: Aug 19, 2008